BC Platforms

BC Platform (BCP) has developed a genomic data discovery and analytics platform that collects biological information for research and drug discovery. As of January 2023, BCP gave access to real-world data of 33 million+ subjects and had plans to increase this to 100 million by 2026. The platform also enables precision medicine by matching patients with targeted therapies. 

Its geographic data coverage includes the EU, America, Asia-Pacific, and Africa, covering disease areas such as cardiovascular, solid tumor, oncology and neurology. Its core solution is its Trusted Collaboration Environment (TCE), which enables data sharing within healthcare organizations and researchers while adhering to its respective legal requirements. Its other products include 1) BC Insight, which is a data and research platform for clinical genomic studies, 2) BC Genome, which is a data management and analysis platform for healthcare providers and labs, and 3) BC Rquest, which provides analysis and tools for biobanks. 

As of November 2022, the company had operations in the US, the UK, Finland, Switzerland, and Singapore.

Key Customers and Partnerships

The company’s key customers include more than 10 global big pharma companies. It has over 17 data partners globally including Singapore’s largest healthcare provider SingHealth (since March 2022), data analytic giant SAS Institute (since April 2022), African Institute of Everyone Genome (since September 2021), non-profit organization CureDuchenne focusing on Duchenne muscular dystrophy research (since June 2021), Japanese-based bioinformatics company Mitsubishi Space Software (since February 2022), Southeast Asia’s largest hospital Bumrungrad International Hospital (since October 2021), and Colorado Center for Personalized Medicine (since December 2021).

The company also has several strategic partnerships including 1) software provider Genomenon to combine technologies into two BCP products; BC Genome and BC Insight (since February 2021), 2) Helsinki University Hospital to collaborate on an EU project ONCOVALUE by providing its data analysis expertise under TCE to assess the effectiveness of cancer therapies (in November 2022), 3) Pfizer Finland to provide its platform to study cardiovascular diseases (in February 2018), and 4) diagnostic company Crestar Labs to enhance cancer screening for precision medicine (in March 2019). 

Funding and Financials

The company raised USD 20 million in November 2022 via a growth equity financing round led by private equity firm Jolt Capital. The new funds were allocated toward expanding its data footprint with a focus on gathering real-world data from European and Asian countries, for its R&D, and sales and marketing operations.